The burden of non-communicable diseases (NCDs), particularly cancer, is steadily increasing in Kazakhstan alongside socioeconomic development, highlighting the urgent need for effective national management and control strategies. The Electronic Registry of Oncological Patients (EROP) is a key initiative designed to support this goal by enabling comprehensive surveillance of cancer patients across the country. This review examines the patient journey that informs EROP’s data collection process and explores its potential as a foundation for local cancer epidemiology research. Analysis of the registry reveals extensive coverage of dispensary, outpatient, and inpatient visits, capturing detailed socio-demographic information, diagnoses, treatments, and mortality outcomes. EROP provides valuable insights into cancer morbidity, mortality, and quality of life across spatial and temporal dimensions in Kazakhstan. The review also addresses current limitations and underexplored aspects of the registry, emphasizing the importance of careful interpretation to ensure robust, evidence-based research.

There is a scarcity of publications evaluating the performance of the national liver transplantation (LTx) program in Kazakhstan. Spanning from 2012 to 2023, it delves into historical trends in LTx surgeries, liver transplant centers, and the national cohort of patients awaiting LTx. Survival analysis for those awaiting LTx, using life tables and Kaplan–Meier, is complemented by time series analysis projecting developments until 2030. The overall per million population (pmp) LTx rate varied from 0.35 to 3.77, predominantly favoring living donor LTx. Liver transplant center rates ranged from 0.06 to 0.40. Of 474 LTx patients, 364 on the waiting list did not receive transplantation. The 30-day and 1-year survival rates on the waiting list were 87.0% and 68.0%, respectively. Viral hepatitis and cirrhosis prevalence steadily rose from 2015 to 2023, with projections indicating a persistent trend until 2030. Absent targeted interventions, stable pmp rates of LTx and liver transplant centers may exacerbate the backlog of unoperated patients. This study sheds light on critical aspects of the LTx landscape in Kazakhstan, emphasizing the urgency of strategic interventions to alleviate the burden on patients awaiting transplantation.

This prospective study evaluates the impact of radiofrequency ablation (RFA) on cardiorespiratory indicators in patients with long-standing persistent atrial fibrillation admitted to the Heart Center UMC between January 2022 and April 2024 in Astana, Kazakhstan. The study aims to assess the functional cardiac benefits of RFA. Out of 717 registered atrial fibrillation patients, 104 were examined before and 3 months after ablation, focusing on cardiorespiratory parameters. A before-and-after analysis using linear mixed models was applied to evaluate changes in cardiorespiratory parameters post-RFA. Significant improvements were noted across various measures. VO₂ max increased from 11.5 ± 4.4 mL/kg/min to 18.0 ± 4.5 mL/kg/min (p < 0.001). Oxygen uptake improved from 7.2 ± 2.6 mL/beat to 11.0 ± 3.4 mL/beat (p < 0.001). The 6-min walking test distance rose from 306 ± 82 m to 400 ± 48 m (p < 0.001). METs increased from 4.4 ± 1.6 to 8.0 ± 1.3 (p < 0.001). Heart rate at peak exercise decreased from 175.5 ± 18.6 to 147.2 ± 12.3 beats per minute (p < 0.001). NT-proBNP levels decreased from 1357 ± 1182 to 415 ± 339 pg/mL (p < 0.001). Patients with persistent atrial fibrillation undergoing RFA showed functional improvements in CPET indicators such as VO₂ max, METs, O₂ pulse, heart rate, and the 6-min walking test. Improvements were also seen in Nt-proBNP analysis. These results emphasize the need for longitudinal follow-up to optimize outcomes and minimize medical risks.